Clinical Trial Update: Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating tissue kallikrein to prevent restenosis after stenting in patients with symptomatic middle cerebral artery atheroscle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebrovascular Disease

Drugs mentioned

• Tissue kallikrein (tissue kallikrein)

Snippet

Sponsor: Jinling Hospital, China | Conditions: Cerebrovascular Disease | Phase 2 | Status: UNKNOWN